Filtered By:
Condition: Atrial Fibrillation
Therapy: Statin Therapy

This page shows you your search results in order of relevance. This is page number 10.

Order by Relevance | Date

Total 237 results found since Jan 2013.

Association between pericoronary adipose tissue attenuation and outcome after second-generation cryoballoon ablation for atrial fibrillation
CONCLUSION: Pre-ablation CTA-derived 3V-PCATA, representing pericoronary inflammation, was an independent predictor of recurrence after first-session AF ablation using a second-generation cryoballoon.ADVANCES IN KNOWLEDGE: Assessment of 3V-PCATA may identify patients at high risk of AF recurrence after CBA for AF.PMID:34520243 | DOI:10.1259/bjr.20210361
Source: The British Journal of Radiology - September 14, 2021 Category: Radiology Authors: Kai Nogami Tomoyo Sugiyama Yoshihisa Kanaji Masahiro Hoshino Satoshi Hara Masao Yamaguchi Masahiro Hada Yohei Sumino Toru Misawa Hidenori Hirano Hiroki Ueno Naoyuki Miwa Kazuya Yamao Shigeki Kusa Hitoshi Hachiya Tsunekazu Kakuta Source Type: research

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients with Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
Conclusions: In REDUCE-IT, icosapent ethyl reduced fatal and nonfatal ischemic events across the broad range of baseline eGFR categories. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT01492361.PMID:34706555 | DOI:10.1161/CIRCULATIONAHA.121.055560
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Arjun Majithia Deepak L Bhatt Allon N Friedman Michael Miller Ph Gabriel Steg Eliot A Brinton Terry A Jacobson Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz Matthew Budoff R Preston Mason Jean-Claude Tardif William E Boden Ch Source Type: research

Icosapent Ethyl Reduces Ischemic Events in Patients with a History of Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG
Conclusions: In REDUCE-IT patients with a history of CABG, treatment with icosapent ethyl was associated with significant reductions in first and recurrent ischemic events.PMID:34710343 | DOI:10.1161/CIRCULATIONAHA.121.056290
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Subodh Verma Deepak L Bhatt Ph Gabriel Steg Michael Miller Eliot A Brinton Terry A Jacobson Nitish K Dhingra Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz C Michael Gibson Duane Pinto Robert P Giugliano Matthew J Budoff R Pre Source Type: research

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients with Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
Conclusions: In REDUCE-IT, icosapent ethyl reduced fatal and nonfatal ischemic events across the broad range of baseline eGFR categories. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT01492361.PMID:34706555 | DOI:10.1161/CIRCULATIONAHA.121.055560
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Arjun Majithia Deepak L Bhatt Allon N Friedman Michael Miller Ph Gabriel Steg Eliot A Brinton Terry A Jacobson Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz Matthew Budoff R Preston Mason Jean-Claude Tardif William E Boden Ch Source Type: research

Icosapent Ethyl Reduces Ischemic Events in Patients with a History of Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG
Conclusions: In REDUCE-IT patients with a history of CABG, treatment with icosapent ethyl was associated with significant reductions in first and recurrent ischemic events.PMID:34710343 | DOI:10.1161/CIRCULATIONAHA.121.056290
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Subodh Verma Deepak L Bhatt Ph Gabriel Steg Michael Miller Eliot A Brinton Terry A Jacobson Nitish K Dhingra Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz C Michael Gibson Duane Pinto Robert P Giugliano Matthew J Budoff R Pre Source Type: research

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients with Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
Conclusions: In REDUCE-IT, icosapent ethyl reduced fatal and nonfatal ischemic events across the broad range of baseline eGFR categories. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT01492361.PMID:34706555 | DOI:10.1161/CIRCULATIONAHA.121.055560
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Arjun Majithia Deepak L Bhatt Allon N Friedman Michael Miller Ph Gabriel Steg Eliot A Brinton Terry A Jacobson Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz Matthew Budoff R Preston Mason Jean-Claude Tardif William E Boden Ch Source Type: research

Icosapent Ethyl Reduces Ischemic Events in Patients with a History of Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG
Conclusions: In REDUCE-IT patients with a history of CABG, treatment with icosapent ethyl was associated with significant reductions in first and recurrent ischemic events.PMID:34710343 | DOI:10.1161/CIRCULATIONAHA.121.056290
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Subodh Verma Deepak L Bhatt Ph Gabriel Steg Michael Miller Eliot A Brinton Terry A Jacobson Nitish K Dhingra Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz C Michael Gibson Duane Pinto Robert P Giugliano Matthew J Budoff R Pre Source Type: research

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients with Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
Conclusions: In REDUCE-IT, icosapent ethyl reduced fatal and nonfatal ischemic events across the broad range of baseline eGFR categories. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT01492361.PMID:34706555 | DOI:10.1161/CIRCULATIONAHA.121.055560
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Arjun Majithia Deepak L Bhatt Allon N Friedman Michael Miller Ph Gabriel Steg Eliot A Brinton Terry A Jacobson Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz Matthew Budoff R Preston Mason Jean-Claude Tardif William E Boden Ch Source Type: research

Impact of Low-density Lipoprotein Cholesterol Levels on Outcomes in Nonvalvular Atrial Fibrillation: Results from the China Atrial Fibrillation Registry Study
CONCLUSIONS In patients with NVAF using standard or no lipid-lowering medication, low plasma LDL-C levels were related to an increased risk of stroke/thromboembolism and cardiovascular mortality.PMID:35418552 | DOI:10.12659/MSM.934747
Source: Medical Science Monitor - April 14, 2022 Category: Research Authors: Zhi-Zhao Li Xin Du Nian Liu Xue-Yuan Guo Chao Jiang Liu He Shi-Jun Xia Wei Wang Ri-Bo Tang San-Shuai Chang Rong-Hui Yu De-Yong Long Rong Bai Cai-Hua Sang Song-Nan Li Jian-Zeng Dong Chang-Sheng Ma Source Type: research

Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial)
Introduction The world is undergoing a demographic transition to an older population. Preventive healthcare has reduced the burden of chronic illness at younger ages but there is limited evidence that these advances can improve health at older ages. Statins are one class of drug with the potential to prevent or delay the onset of several causes of incapacity in older age, particularly major cardiovascular disease (CVD). This paper presents the protocol for the STAtins in Reducing Events in the Elderly (STAREE) trial, a randomised double-blind placebo-controlled trial examining the effects of statins in community dwelling o...
Source: BMJ Open - April 3, 2023 Category: General Medicine Authors: Zoungas, S., Curtis, A., Spark, S., Wolfe, R., McNeil, J. J., Beilin, L., Chong, T. T.-J., Cloud, G., Hopper, I., Kost, A., Nelson, M., Nicholls, S. J., Reid, C. M., Ryan, J., Tonkin, A., Ward, S. A., Wierzbicki, A., On behalf of STAREE investigator group Tags: Open access, Cardiovascular medicine Source Type: research

Statins Tied to Lower Stroke Risk in Atrial Fibrillation Statins Tied to Lower Stroke Risk in Atrial Fibrillation
Initiation of statins soon after diagnosis of AF is associated with lower risk of ischemic and hemorrhagic strokes; longer-term use is tied to further benefit, a new study shows.Medscape Medical News
Source: Medscape Cardiology Headlines - April 28, 2023 Category: Cardiology Tags: Cardiology News Source Type: news

Comparison of Rosuvastatin versus Atorvastatin for Preventing Postoperative Atrial Fibrillation.
Conclusions: The present study revealed that preoperative rosuvastatin or atorvastatin treatment did not have a different effect in preventing postoperative AF. PMID: 23803242 [PubMed - in process]
Source: The Heart Surgery Forum - June 1, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Abaci O, Kocas C, Oktay V, Yildiz CE, Kilickesmez KO, Coskun U, Yildiz A, Yigit Z Tags: Heart Surg Forum Source Type: research

Statin therapy prior to CABG surgery may improve outcomes
Patients receiving statin therapy before coronary artery bypass grafting (CABG) surgery appear to have a reduced risk of post-surgical mortality, stroke, and atrial fibrillation (irregular or rapid heart rate), according to an article in the October 2013 issue of The Annals of Thoracic Surgery. These same benefits from statins could not be demonstrated for patients undergoing aortic valve replacement (AVR). "Heart surgery patients typically have a number of other disorders, so we need to optimize the patient's preoperative condition and help ensure the best possible result," said Elmar W...
Source: Health News from Medical News Today - October 1, 2013 Category: Consumer Health News Tags: Statins Source Type: news